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Objectives This study sought to assess whether transradial intervention, by minimizing access-site
bleeding and vascular events, improves outcomes in patients with ST-segment elevation myocardial
infarction compared with the transfemoral approach.
Background Bleeding and consequent blood product transfusions have been causally associated
with a higher mortality rate in patients with myocardial infarction undergoing coronary angioplasty.
Methods We identiﬁed all adults undergoing percutaneous intervention for acute myocardial infarction
in Emilia-Romagna, a region in the north of Italy of 4 million residents, between January 1, 2003, and
July 30, 2009, at 12 referral hospitals using a region-mandated database of percutaneous coronary inter-
vention procedures. Differences in the risk of death at 2 years between patients undergoing transfemoral
versus transradial intervention, assessed on an intention-to-treat basis, were determined from vital statis-
tics records and compared based on propensity score adjustment and matching.
Results A total of 11,068 patients were treated for acute myocardial infarction (8,000 via transfemo-
ral and 3,068 via transradial route). According to analysis of matched pairs, the 2-year, risk-adjusted
mortality rates were lower for the transradial than for the transfemoral group (8.8% vs. 11.4%;
p  0.0250). The rate of vascular complications requiring surgery or need for blood transfusion were
also signiﬁcantly decreased in the transradial group (1.1% vs. 2.5%, p  0.0052).
Conclusions In patients undergoing angioplasty for acute myocardial infarction, transradial treat-
ment is associated with decreased 2-year mortality rates and a reduction in the need for vascular
surgery and/or blood transfusion compared with transfemoral intervention. (J Am Coll Cardiol Intv
2012;5:23–35) © 2012 by the American College of Cardiology Foundation
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24Percutaneous coronary intervention (PCI) for acute myo-
cardial infarction reduces the rates of death and recurrent
ischemia compared with medical therapy (1).
Transfemoral access (TFA) is the preferred and most widely
used percutaneous access site in most cardiac catheterization
laboratories worldwide. Being a relatively deep and terminal vessel,
however, the femoral artery may expose the patient to rare
ischemic but frequent bleeding and vascular complications (2,3),
especially in the setting of myocardial infarction where potent
antithrombotic drugs are frequently used (4,5).
In registries, bleeding has been consistently associated with
worse outcomes in patients undergoing coronary angioplasty
(5–9). Similarly, 2 distinct pharmacological strategies that were
able to reduce hemorrhagic events have concomitantly lowered
cardiac mortality in randomized trials of patients affected by
myocardial infarction (10,11), a finding that was not explained by
the effect of treatment on ischemic endpoints, such as myocardial
infarction, stroke, or recurrent angina (10,11). Therefore, a new
paradigm has emerged, according
to which bleeding prevention itself
may improve survival in patients
with acute myocardial infarction
undergoing invasive coronary man-
agement (12,13).
After the Campeau et al. (14)
report of successful coronary an-
giography by transradial access
(TRA), the radial artery has been
increasingly employed as an alter-
native access site to the femoral
artery for both diagnostic and in-
terventional procedures. Although
technically more demanding, trans-
radial intervention (TRI) offers the
advantage of minimal access-site
vascular complications (15). Yet, in
he emergent setting of acute myocardial infarction, where a
imely procedure is of paramount importance, and coronary
natomy is unknown, TRI is rarely employed (16).
We conducted a study on an unselected, population-
ased cohort of patients with myocardial infarction who
ere treated with percutaneous mechanical intervention via
ither the transfemoral or the transradial approach. We
ought to determine whether TRI, by minimizing access-
ite bleeding and vascular complications, was associated
ith improved short- to medium-term outcomes compared
ith the traditional transfemoral approach.
Because the access site was not randomly assigned, we
sed propensity score matching to minimize bias.
ethods
Study population. The REAL registry (REgistro regionale
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CI  confidence interval
HR  hazard ratio
IQR  interquartile range
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TFA  transfemoral access
TRA  transradial access
TRI  transradial
interventionngiopLastiche dell’Emilia-Romagna) is a large, prospec-ive, Internet–based registry designed to collect clinical and
ngiographic data on all consecutive PCIs performed in a
egion in northern Italy with 4 million residents. Thirteen
ublic and private centers of interventional cardiology par-
icipated in data collection. Procedural data are retrieved
irectly and continuously from the resident databases of
ach laboratory, which share a common pre-specified data-
et. These data are open for evaluation, and periodic audits
re performed by the Regional Health Care Administration.
etween January 2003 and June 2009, 11,355 patients that
eside in the region underwent PCI for ST-segment eleva-
ion myocardial infarction (STEMI). For 273 patients
2.4%), the access site was not retrievable, whereas 14
atients (0.1%) underwent transbrachial intervention and were
xcluded. The present study population, therefore, consists of
1,068 resident patients, with a median follow-up of 992 days,
ho underwent transfemoral or TRI for acute myocardial
nfarction.
Study subjects were assigned to either the transfemoral or
he transradial group according to the first attempted
rterial access site, based on the intention-to-treat principle.
herefore, patients in whom the first attempted percutane-
us access site was not successful, those who required an
lternative access site before or during intervention, or those
ho underwent transfemoral intra-aortic pump implanta-
ion before, during, or after PCI were categorized based on
he first attempted percutaneous access site. To ensure a
orrect application of the intention-to-treat principle, hos-
ital records of all cases with intended or actual multiple
rterial access sites were reviewed for additional information
y site investigators.
Interventional strategy and device use, including stent
ype, were left to the discretion of the attending physicians.
eriprocedural glycoprotein IIb/IIIa inhibitors and anti-
hrombotic medications were used according to the opera-
or’s decision and current guidelines.
Antiplatelet treatment was prescribed according to cur-
ent standards of treatment, including lifelong aspirin for all
atients and at least 1 month of ticlopidine (250 mg twice
day) or clopidogrel (75 mg/day) treatment for patients
ho underwent stenting.
The REAL registry is based on current clinical practice;
herefore, regulatory authorities required only an ordinary
ritten informed consent to perform coronary intervention,
hich was obtained from all patients. The protocol of the
tudy is in accordance with the Declaration of Helsinki.
Study outcomes. Follow-up information was obtained di-
rectly and independently from the Emilia-Romagna Re-
gional Health Agency via an analysis of the hospital’s
discharge records and the mortality registries. This ensures
a complete follow-up for 100% of the patients resident in
the region, including all out-of-hospital deaths (this is the
reason for the priori exclusion of patients who live outside
the region).
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25The primary outcome was death from any cause within 2
years after the index procedure.
Secondary outcomes included recurrent myocardial in-
farction and stroke during follow-up, whereas the main
safety outcome was the rate of major bleeding and vascular
events within 30 days, which were defined as any bleedings
requiring red blood cell transfusion and/or the need for
access-site surgical repair.
Statistical analysis. Because the patients were not randomly
assigned to undergo TRI, a propensity score analysis was
performed by using a logistic regression model for TRI
versus transfemoral intervention to adjust for differences in
baseline characteristics.
This analysis was conducted according to a nonparsimo-
nious approach, and it included a number of clinical,
angiographic, and procedural variables, which are listed in
Table 1, plus year and site of treatment. We performed a
1-to-1 matched analysis without replacement on the basis of
the estimated propensity score of each patient. The log odds
of the probability that a patient received TRI on an
intention-to-treat basis (the “logit”) was modeled as a
function of the confounders that we identified and included
in our dataset. Using the estimated logits, we first randomly
selected a patient in the group receiving TRI and then
matched that patient with the patient in the group under-
going transfemoral PCI with the closest estimated logit
value. Patients in the group receiving transfemoral PCI who
had an estimated logit within 0.25 SD of the selected
patients in the group undergoing TRI were eligible for
matching. We selected 0.25 because this value has been
shown to eliminate more than 90% of the bias in observed
confounders (17). If more than 1 patient in the group
receiving transfemoral PCI met this criterion, we randomly
selected 1 patient for matching. We analyzed the data
according to 2 different propensity score models: 1 for any
STEMI, and 1 restricted to individuals who were free from
cardiogenic shock at the time of presentation. The decision
to exclude patients with cardiogenic shock in the second
propensity score model was based on the observation that
severe hemodynamic instability at presentation emerged as
the single most influential covariate for the propensity to
undergo TRI in our real-world registry. To assess the
success of the matching procedure, the estimates of the
percentage reduction in bias from propensity score
matching was measured by calculating an initial bias (as
the difference in covariate mean values between groups
before matching, bi) and the post-matching bias (as the
difference in covariate mean values after matching, bm)
and then calculating the percentage reduction in bias as:
100(1  bm/bi) (18).
After all the propensity score matches were performed,
we compared the baseline covariates between the 2 inter-
vention groups. Continuous variables were compared using
the paired t test or the Wilcoxon signed rank test, asappropriate, and categorical variables were compared using
McNemar test. The statistical significance and the effect of
treatment on outcomes were estimated using appropriate
statistical methods for matched data (18,19). In the propen-
sity score–matched cohort, the risks of each outcome were
compared using Cox regression models, with robust stan-
dard errors that accounted for the clustering of matched
pairs. Survival curves were also constructed with Kaplan-
Meier estimates and compared by the Klein-Moeschberger
test (20).
Because it has been suggested that combining multiple
techniques with propensity score models may yield to a
better estimator of treatment effect than deriving the treat-
ment effect with any of the 3 available methods (i.e.,
matching, stratification, or regression adjustment) alone
(18), the propensity score that was generated in the whole
patient population (i.e., without the exclusion of patients
with cardiogenic shock) was then incorporated into subse-
quent proportional-hazards models as a covariate. To avoid
overadjustment, the multivariable Cox regression analysis
was performed using only the 2 variables “propensity score”
and “treatment.”
To investigate the associations between the occurrence of
major bleeding and vascular events within 30 days with the
incidence of 2-year mortality, an additional multivariable
Cox model was fitted with the adverse event as a time-
updated binary covariate and with adjustment achieved based
on the propensity score. Finally, the contribution of a major
bleeding or vascular event within 30 days to 2-year mortality,
the so-called attributable risk was calculated using the follow-
ing formula: AR  PF (adjHR  1)/[PF(adjHR  1)  1],
where PF is the prevalence of the adverse events within the
studied population, AR is the attributable risk, and adjHR
is the adjusted hazard ratio obtained with the multivari-
able time-updated Cox model. All reported p values are
2-sided, and p values of 0.05 were considered to
indicate statistical significance. SAS software, version 9.1
(SAS Institute, Cary, North Carolina) was used for
statistical analyses. All analyses have been performed by
an independent statistician (P.G.) working full time for
the Emilia-Romagna region.
Results
Between January 1, 2003, and June 30, 2009, there were
12,407 adult patients who underwent PCI for STEMI in
Emilia Romagna. We excluded 1,052 patients who were not
residents of Emilia Romagna, 273 patients whose primary
intended access site was not identifiable, and 14 patients in
whom the primary intended access site was the brachial
artery. The resulting cohort of 11,068 underwent PCI by 53
operators at 12 hospitals. Of these patients, 8,000 (median
follow-up: 1,204 days) underwent transfemoral and 3,068
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26Table 1. Characteristics of the Patients Before Propensity Score Matching
Characteristic
Transradial
(n  3,068)
Transfemoral
(n  8,000) p Value
Age, yrs 65.2 12.5 66.6 13.2 0.0001
Male 76.7 69.8 0.0001
Diabetes 32 (24.4) 37 (28.0) 0.0914
Body mass index, kg/m2 27.3 4.3 26.8 4.1 0.0001
Hypertension 59.6 60.3 0.5212
Hyperlipidemia 49.2 44.2 0.0001
Current cigarette use 34.4 31.9 0.0139
Systolic blood pressure, mm Hg 125.5 24.8 124.4 29.1 0.0783
Heart rate, beats/min 76.0 23.9 77.3 20.5 0.0106
Prior myocardial infarction 10.5 14.7 0.0001
Prior percutaneous coronary intervention 8.1 8.8 0.229
Prior coronary bypass surgery 1.6 2.8 0.0006
Left ventricular ejection fraction 35% 8.5 13.6 0.0001
Chronic lung disease 6.4 6.9 0.369
History of heart rhythm disturbances 3.0 4.4 0.0011
Chronic kidney disease 5.3 5.9 0.225
Dialysis 0.1 0.6 0.0010
History of neoplasm 6.6 7.1 0.375
History of heart failure 6.2 19.6 0.0001
History of anemia 1.0 1.3 0.180
Previous bleeding 1.5 2.1 0.0438
Prior red blood cell transfusion 1.6 2.0 0.152
Red blood cell transfusion in the previous 365 days 0.1 0.6 0.0010
Cardiogenic shock 3.8 13.4 0.0001
Intra-aortic balloon pump 1.8 9.0 0.0001
Invasive mechanical ventilation 1.4 4.9 0.0001
Use of glycoprotein IIb/IIIa inhibitor 83.1 81.8 0.112
Warfarin therapy 3.5 3.5 0.948
Multivessel disease 68.8 72.7 0.0004
Infarct-related artery
Left main stem 0.4 0.9 0.0004
Left anterior descending artery 45.6 48.6 0.0060
Left circumﬂex artery 16.3 13.1 0.0001
Right coronary artery 36.9 36.1 0.449
Bypass vein graft 0.7 1.2 0.0238
Baseline TIMI ﬂow grade 0–1 62.6 69.1 0.0001
Lesion length, mm 19.9 10.1 20.0 10.0 0.782
Reference vessel diameter, mm 3.0 0.5 3.0 0.5 0.851
Total stent length, mm 23.2 11.0 23.5 11.5 0.244
Ostial disease as culprit lesion 5.6 8.3 0.0001
Bifurcation disease as culprit 23.0 16.1 0.0001
Type C lesion as culprit 40.5 45.6 0.0001
Balloon angioplasty only 9.8 11.1 0.0510
Stent implantation without prior dilation 29.2 22.7 0.0001
Bare-metal stent implantation in the culprit lesion 75.1 75.5 0.640
Drug-eluting stent implantation in the culprit lesion 15.1 13.4 0.0200
Angiographic success 96.5 95.1 0.0015
Values are mean SD or n (%). Percentages may not total 100 because of rounding.TIMI Thrombolysis In Myocardial Infarction.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 , 2 0 1 2 Valgimigli et al.
J A N U A R Y 2 0 1 2 : 2 3 – 3 5 Transradial Intervention for Myocardial Infarction
27(median follow-up: 605 days) were primarily treated with
TRI. The rate of TRI greatly increased over time, from
2% in 2003 to 60% in 2009 (Fig. 1). The rate of
cross-over from primarily indented TRA to TFA increased
from 0% in 2003, up to 7.5% in 2006, and then stabilized at
around 3.5% through 2008 and 2009.
Unadjusted outcomes. Before propensity score matching,
patients who underwent transfemoral intervention and
those intended to undergo transradial approach differed
significantly in clinical and procedural characteristics (Table 1).
Male patients of a younger age with no previous history of
coronary artery bypass grafting, with stable hemodynamic
conditions, higher body mass index, yet with a less frequent
history of previous blood cell transfusion were more likely to
be treated transfemorally. The unadjusted rates of death
within 2 years was lower (9.3% vs. 16.7%, p 0.001) among
patients undergoing TRI, which was largely driven by a
mortality difference observed in the first 30 days after
treatment (3.6% vs. 8.7%, p  0.001). The composite of
death or myocardial infarction and the rate of death,
myocardial infarction, or stroke were also lower in the
transradial group.
Similarly, the rate of major bleeding or vascular events
was significantly reduced in the transradial as compared
with the transfemoral group at 30 days (1.1% vs. 2.6%) and
at 2 years (4.9% vs. 6.9%, p 0.001), but not between 1 and
24 months (3.9% vs. 4.5%, p  0.230).
The lower rates for both mortality (7.9% vs. 10.9%, p 
0.001) and major bleeding and vascular events (1.0% vs.
2.3%, p  0.001) remained consistently in favor of the
transradial group after exclusion of patients with cardiogenic
shock.
Outcomes for the matched cohorts. After propensity score
matching was performed for the entire population, there were
1,501 matched pairs of patients (Table 2). The area under the
receiver-operating characteristic curve for this model was
0.906. Median percent reduction in bias was as high as 76.5%
Figure 1. Temporal Trends of Transradial and Transfemoral Intervention DuProportions do not always add up to 100% due to incomplete data reporting and u(interquartile range [IQR]: 61.5% to 88.6%), with no improve-
ment noted for 4 covariates only (i.e., hypertension, lesion
length, warfarin treatment, and bare-metal stenting in the
infarct-related artery) which all appeared evenly distributed
between groups before matching techniques were imple-
mented and remained as such thereafter. This result sup-
ports the assumption of balance between treatment groups in
observed confounders. A separate propensity score match was
also performed after the exclusion of patients who had cardi-
ogenic shock during index hospitalization (1,382 matched
pairs; area under the curve: 0.904). Median percent reduction
in bias was as high as 77.8% (IQR: 65.5% to 91.9%).
In these matched cohorts, there was no longer any
significant difference between the transradial and the trans-
femoral group for any covariate, according to the use of
statistical methods appropriate for matched data (Table 2).
With respect to the primary outcome, TRI, compared
with transfemoral intervention, was associated with a sig-
nificantly lower mortality at 2 years (8.8% vs. 11.4%, hazard
ratio [HR]: 1.303; 95% confidence interval [CI]: 1.034 to
1.642; p  0.0250) (Fig. 2A, Table 3).
The rates of myocardial infarction (Fig. 2B) or stroke
(Fig. 2C) did not differ at 2 years in patients who underwent
TRI as compared with the transfemoral group, yet both
composite of death or myocardial infarction, and death,
myocardial infarction, or stroke (Fig. 2D) were lower in the
transradial group at 2 years, entirely driven by the observed
difference in mortality between groups (Table 3).
At subgroup analysis, the mortality benefit favoring the
transradial access site appeared consistent across key pre-
selected covariates (Fig. 2E).
In the matched cohort of patients without cardiogenic
shock, mortality and the composite of death, myocardial
infarction, or stroke was also consistently reduced in the
transradial group (Table 3, Fig. 3).
After propensity score matching, the rate of major
bleeding and vascular events was significantly reduced at
e Study Periodring thse of the brachial access site.
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28Table 2. Characteristics of the Propensity Score–Matched Patients
Characteristic
Overall Patient Population Patients Without Cardiogenic Shock
Transradial
(n  1,501)
Transfemoral
(n  1,501) p Value
Transradial
(n  1,382)
Transfemoral
(n  1,382) p Value
Age, yrs 66.1 12.4 65.7 13.1 0.426 65.6 12.6 65.5 12.9 0.936
Male 74.7 74.6 0.933 75.3 74.8 0.757
Diabetes 20.1 20.8 0.618 19.6 19.5 0.961
Body mass index, kg/m2 27.3 4.3 26.8 4.0 0.288 27.3 4.3 26.9 4.0 0.186
Hypertension 61.0 60.4 0.707 60.2 61.4 0.507
Hyperlipidemia 48.3 47.9 0.827 48.1 47.3 0.667
Current cigarette use 33.3 33.8 0.968 34.4 34.8 0.935
Systolic blood pressure, mm Hg 126.4 25.6 126.0 28.3 0.855 128.7 24.6 128.6 26.3 0.497
Heart rate, beats/min 75.4 16.4 75.7 26.8 0.904 74.9 16.0 74.9 17.9 0.781
Time from symptoms onset to hospital presentation, min 208 96 210 89 0.798 198 88 197 89 0.984
Time from hospital presentation to angioplasty, min 88 65 86 64 0.687 81 59 80 58 0.887
Prior myocardial infarction 11.9 11.9 0.954 11.6 12.2 0.639
Prior percutaneous coronary intervention 8.1 8.5 0.740 8.0 8.7 0.498
Prior coronary bypass surgery 1.9 1.7 0.680 1.7 1.9 0.777
Left ventricular ejection fraction 35% 8.9 9.8 0.732 8.0 7.8 0.902
Chronic lung disease 7.5 6.5 0.322 6.9 7.1 0.879
History of heart rhythm disturbances 3.1 3.5 0.540 3.0 3.0 0.913
Chronic kidney disease 5.1 5.3 0.744 5.1 5.2 0.864
Dialysis 0.2 0.1 0.317 0.1 0.1 0.564
History of neoplasm 7.2 6.9 0.774 6.4 7.5 0.236
History of heart failure 6.9 7.0 0.942 5.9 6.6 0.420
History of anemia 1.0 1.2 0.590 1.0 1.0 1.000
Previous bleeding 1.7 1.6 0.777 1.6 1.5 0.879
Prior red blood cell transfusion 1.5 1.3 0.647 1.6 1.3 0.527
Red blood cell transfusion in the previous 365 days 0.2 0.1 0.317 0.1 0.1 0.5564
Cardiogenic shock 4.9 5.5 0.414 0 0 —
Intra-aortic balloon pump 2.9 2.7 0.825 1.3 1.2 0.865
Invasive mechanical ventilation 1.5 1.9 0.484 0.7 0.4 0.439
Use of glycoprotein IIb/IIIa inhibitor 79.7 79.6 0.964 80.5 81.6 0.465
Warfarin therapy 3.5 3.6 0.922 3.2 3.0 0.827
Multivessel disease 73.4 71.9 0.867 72.0 71.5 0.507
Multivessel intervention 3.4 3.1 0.606 3.2 3.0 0.741
Infarct-related artery
Left main stem 0.6 0.5 0.808 0.4 0.2 0.480
Left anterior descending artery 46.7 47.6 0.629 46.8 47.3 0.826
Left circumﬂex artery 15.3 15.4 0.960 15.8 14.9 0.532
Right coronary artery 36.6 35.6 0.594 36.4 36.8 0.816
Bypass vein graft 0.8 0.9 0.842 0.7 0.8 0.655
Baseline TIMI ﬂow grade 0–1 65.8 65.8 0.969 65.1 64.7 0.845
Lesion length, mm 19.9 10.1 19.7 9.4 0.565 19.6 9.9 19.6 9.7 0.866
Reference vessel diameter, mm 3.0 0.5 3.0 0.5 0.689 3.0 0.5 3.0 0.5 0.840
Total stent length, mm 22.8 10.9 23.0 10.6 0.334 22.7 10.8 23.0 10.7 0.330
Ostial disease as culprit lesion 6.5 6.6 0.882 5.7 5.6 0.931
Bifurcation disease as culprit 21.2 29.6 0.688 21.2 20.7 0.742
Type C lesion as culprit 40.1 41.7 0.633 40.3 41.5 0.198
Balloon angioplasty only 7.6 8.1 0.633 7.2 8.1 0.398
Stent implantation without prior dilation 26.9 26.6 0.871 26.8 26.9 0.931
Bare-metal stent implantation in the culprit lesion 75.4 75.3 0.966 75.7 74.9 0.626
Drug-eluting stent implantation in the culprit lesion 17.0 16.6 0.773 17.1 17.0 0.959
Angiographic success 97.9 97.5 0.622 98.1 98.4 0.555
Values are mean SD or %.TIMI Thrombolysis In Myocardial Infarction.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 , 2 0 1 2 Valgimigli et al.
J A N U A R Y 2 0 1 2 : 2 3 – 3 5 Transradial Intervention for Myocardial Infarction
29Figure 2. Kaplan-Meier Curves for Outcomes in the Propensity Score–Matched Cohort of Patients
Patients who underwent transradial or transfemoral intervention were matched for propensity scores. Propensity matching for the entire cohort created 1,501
matched pairs of patients. (A) Shown are the outcomes for overall survival; (B) outcomes for myocardial infarction; (C) outcomes for stroke; (D) outcomes for
overall death, myocardial infarction, or stroke; and (E) shows the hazard ratios for overall survival at 2 years according to selected subgroups of study patients.
Event-free survival rates were derived from paired Kaplan-Meier curves.
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3030 days by more than 50% in the transradial group (Table 3),
a treatment effect that was consistent in the matched
cohort of patients who did not suffer from cardiogenic
shock (Table 3).
Table 3. Clinical Outcomes in the Propensity Score–Matched Population
Outcomes
Overall Patient Population
Kaplan-Meier Estimates
Transradial
Group
(n  1,501)
Transfemoral
Group
(n  1,501)
Haz
(
30 days
All-cause death 3.4 4.6 1.363
Myocardial infarction 1.4 1.0 0.672
All-cause death or myocardial infarction 4.7 5.4 1.165
Stroke 0.2 0.1 0.337
All-cause death, myocardial infarction,
or stroke
4.9 5.5 1.130
Major bleeding and vascular events 1.1 2.5 2.288
Major bleeding and vascular events
within index hospitalization
0.8 2.2 2.794
2 yrs
All-cause death 8.8 11.4 1.303
Myocardial infarction 5.7 6.9 1.189
All-cause death or myocardial infarction 13.1 16.6 1.265
Stroke 1.2 1.7 1.280
All-cause death, myocardial infarction,
or stroke
13.9 17.7 1.268
Major bleeding and vascular events 4.8 5.8 1.251
Values are % unless otherwise indicated.
CI confidence interval.
Figure 3. Kaplan-Meier Curves for Outcomes in a Propensity Score–Matche
Patients underwent transradial or transfemoral intervention and were matched for
ated 1,382 matched pairs of patients. (A) Shown are the outcomes for overall surv
rates were derived from paired Kaplan-Meier curves.This difference in both the whole matched cohort of
patients (Fig. 4A, Table 3) or in those matched without
cardiogenic shock (Fig. 4B, Table 3) was entirely due to
events which occurred during the index hospitalization,
Patients Without Cardiogenic Shock
Kaplan-Meier Estimates
tios
I) p Value
Transradial
Group
(n  1,382)
Transfemoral
Group
(n  1,382)
Hazard Ratios
(95% CI) p Value
1.964) 0.097 1.8 2.9 1.611 (0.980–2.648) 0.0599
1.326) 0.252 1.4 1.0 0.743 (0.371–1.488) 0.402
1.612) 0.358 3.1 3.8 1.241 (0.828–1.860) 0.295
3.244) 0.346 0.1 0.1 0.504 (0.046–5.567) 0.576
1.558) 0.454 3.3 3.9 1.207 (0.811–1.798) 0.353
4.089) 0.0052 1.2 2.0 1,774 (0.971–3.243) 0.0625
5.427) 0.0015 0.9 1.9 2.193 (1.124–4.279) 0.0213
1.642) 0.0250 6.8 9.8 1.474 (1.121–1.938) 0.0055
1.618) 0.271 5.7 6.6 1.136 (0.828–1.558) 0.429
1.536) 0.0174 11.3 14.9 1.319 (1.066–1.632) 0.0109
2.432) 0.452 1.0 2.1 1.940 (0.976–3.855) 0.0587
1.530) 0.0130 12.0 16.1 1.344 (1.092–1.654) 0.0052
1.758) 0.196 4.8 5.5 1.168 (0.817–1.669) 0.395
ort of Patients Without Cardiogenic Shock
nsity scores. Propensity matching for patients without cardiogenic shock cre-
) outcomes for overall death, myocardial infarction, or stroke. Event-free survivalard Ra
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31whereas bleeding and vascular events occurring after dis-
charge from index hospitalization did not differ in either
group (Table 3).
Propensity score-adjusted outcomes. The adjusted out-
comes based on a propensity score analysis of the whole
population showed a 30% mortality reduction (HR: 1.309;
95% CI: 1.070 to 1.602; p  0.0089) at 2 years in favor
of TRI (Fig. 5A, Table 4), reflecting an early significant
mortality benefit within 30 days after treatment (HR:
1.380; 95% CI: 1.016 to 1.876; p  0.0395), whereas the
death rate between 1 and 24 months did not differ in the
transradial as compared with the transfemoral group
(HR: 1.289; 95% CI: 0.985 to 1.687; p  0.0648). The
omposite endpoints of death or myocardial infarction
HR: 1.240; 95% CI: 1.050 to 1.465; p  0.0114) (Fig.
B) and death, myocardial infarction, or stroke (HR:
.259; 95% CI: 1.069 to 1.481; p  0.0057) (Fig. 5C)
ere also significantly reduced at 2 years in the transra-
ial group (Table 4).
Similarly, the adjusted 30-day rate of major bleeding or
ascular events remained lower in the transradial group
HR: 1.899; 95% CI: 1.116 to 3.229; p  0.018) (Fig. 5D)
with no difference thereafter up to 24 months (HR: 0.919;
95% CI: 0.640 to 1.320; p  0.646) (Table 4).
At subgroup analysis, the adjusted mortality benefit at 2
years favoring the transradial access site appeared largely
consistent across several analyzed covariates (Fig. 5E).
Length of hospitalization. In the overall patient popula-
ion, the unadjusted length of hospitalization was signif-
Figure 4. Kaplan-Meier Curves for Safety Events in a Cohort of Patients W
Patients underwent transradial or transfemoral intervention and were matched
those with cardiogenic shock, created 1,501 and 1,382 matched pairs of patien
vascular events within 30 days in 1,501 matched pairs of patients; (B) the outc
matched pairs of patients.cantly lower in the transradial (median [IQR]: 4 [6 to 8])ompared with the transfemoral group (median [IQR]: 7
5 to 10]; p  0.0001). Similarly, after propensity score
atching, duration of hospitalization remained markedly
horter in the transradial group, both in the whole matched
opulation (median [IQR]: 4 [6 to 8] vs. 6 [5 to 9]; p 
.0001) and in those matched without cardiogenic shock
median [IQR]: 3 [4 to 6] vs. 5 [5 to 8]; p  0.0001).
Contribution of major bleeding or vascular events to 2-year
mortality. The occurrence within 30 days of major bleeding
or vascular events was associated to an adjusted 7-fold
increase of overall mortality at 2 years at a time-updated
regression model (HR: 7.084; 95% CI: 3.482 to 14.410. p
0.0001), with a significant interaction between bleeding or
vascular complications and femoral access site (p  0.047).
Hence, we calculated that 11% of all deaths at 2 years were
attributable to the occurrence within 30 days of major
bleeding or vascular events.
Discussion
We compared the medium-term outcomes as well as the
safety profile of TRI versus transfemoral intervention in
patients with STEMI undergoing primary percutaneous
intervention. Our observational region-wide study, based
on a large and unselected cohort of patients, showed that
TRI was associated with a decreased mortality compared
with the traditional transfemoral approach. The observed
difference in death was not apparently explained by the
incidence of myocardial infarction or stroke, which did
Without Cardiogenic Shock
ropensity scores. Propensity matching for patients, including or excluding
pectively. (A) Shown are the outcomes for in-hospital major bleeding and
for in-hospital major bleeding and vascular events within 30 days in 1,382ith or
for p
ts, res
omesnot differ between groups. By contrast, TRI was associ-
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 , 2 0 1 2
J A N U A R Y 2 0 1 2 : 2 3 – 3 5
Valgimigli et al.
Transradial Intervention for Myocardial Infarction
32ated with a significant and marked reduction of in-
hospital major bleeding or vascular events. Bleeding
Figure 5. Propensity Score–Adjusted Kaplan-Meier Curves for Outcomes in
A total of 11,068 patients underwent transradial or transfemoral intervention.
myocardial infarction; (C) outcomes for overall death, myocardial infarction, or
analyses are shown, with propensity-adjusted hazard ratios and 95% conﬁdenc
patients treated either transradially or transfemorally.and/or blood product transfusions have been causallyassociated with a higher mortality rate in patients with
acute coronary syndromes (ACS) (7–12,21). The trans-
verall Cohort
own are the outcomes for overall survival; (B) outcomes for overall death or
; (D) outcomes for major bleeding or vascular events; and (E) subgroup
rvals, for the primary endpoint of death for any cause among strata ofthe O
(A) Sh
stroke
e interadial approach may improve the survival rate by mini-
te data
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33mizing access-site–related complications and their nega-
tive prognostic consequences, including the relatively rare
need for access-site surgery (22) and the much more
incidental transfusion of blood products (2,22).
As a result of its long history of use, the wide
availability of several dedicated preformed catheters, and
the possibility to exploit relatively large-diameter cathe-
ters and sheaths, should these be necessary for complex
PCI, TFI is currently considered the gold-standard
access site worldwide.
Although several methodological refinements for
puncture technique and sheath management have been
identified in the literature (23,24), access-site complica-
tions remain frequent in clinical practice, especially in
patients undergoing transfemoral coronary intervention
for ACS (2,4,22). This consistent observation across
studies may be explained by the complex interplay be-
tween several factors, including the high-risk patient
profile per se, the emergency nature of intervention, and
the frequent use of more potent antithrombotic treat-
ments in this patient population (13).
Similarly, although several access-site closure devices for
the femoral artery have been developed and tested in clinical
trials, none of them so far have convincingly shown the
ability to reduce major vascular complications compared
with manual compression (25,26).
Compared with the femoral artery, the radial artery is
much more superficial and has a much smaller caliber.
which makes access-site homeostasis after sheath removal
highly predictable even in the presence of systemic antico-
Table 4. Propensity Score–Adjusted HRs for Clinical
Outcomes
30 days
All-cause death
Myocardial infarction
All-cause death or myocardial infarction
Stroke
All-cause death, myocardial infarction or stroke
Major bleeding and vascular events
Major bleeding and vascular events within index hospital
2 yrs
All-cause death
Myocardial infarction
All-cause death or myocardial infarction
Stroke
All-cause death, myocardial infarction, or stroke
Major bleeding and vascular events
Major bleeding and vascular events within index hospital
*Values1 indicate lower event rate in the transradial group; compleagulation (15,27).Several randomized controlled studies of relatively
limited sample size have convincingly shown that TRI
greatly reduces the incidence of access-site major and
minor bleeding complications (15). Yet, none of these
studies were powered to assess whether the use of the
radial instead of the femoral route may translate into an
improved short- to medium-term outcome. A meta-
analysis of 18 randomized trials comparing TRA versus
TFA that mainly focused on elective patients undergoing
coronary angiography and/or ad hoc intervention showed
a 73% reduction of access-site bleeding complications
and a trend toward a 29% reduction of the ischemic
composite endpoint of death, myocardial infarction, or
stroke in the transradial group (27).
A systematic review of the literature involving 2,808
STEMI patients who were largely recruited via nonrandom-
ized comparisons, showed that TRI was associated with a
significant, almost 50% decrease of overall mortality. Mor-
tality in the 516 patients in whom access sites were
randomly allocated was also numerically almost 40% lower
in the transradial group, but this difference failed to reach
statistical significance (28).
In the RIVAL (RadIal Vs femorAL access for coronary
intervention) study, patients randomized to the transradial
arm in the highest tertile for radial PCI center volume
showed a 50% reduction of death, myocardial infarction, or
stroke compared with the transfemoral group, which came
along with a 55% reduction of major bleeding complications
(29). Interestingly, in the 1,958 STEMI study patients, a
41% significant reduction of the composite ischemic end-
point and a 61% reduction of mortality alone were noted in
mes
Adjusted Hazard Ratios
(95% Confidence Interval)* p Values
1.380 (1.016–1.876) 0.0395
0.612 (0.332–1.122) 0.113
1.199 (0.913–1.574) 0.192
0.560 (0.103–3.050) 0.503
1.177 (0.900–1.538) 0.234
1.899 (1.116–3.229) 0.0180
2.306 (1.279–4.156) 0.0055
1.309 (1.070–1.602) 0.0089
1.135 (0.862–1.495) 0.366
1.240 (1.050–1.465) 0.0114
1.855 (1.014–3.393) 0.0450
1.259 (1.069–1.481) 0.0057
1.181 (0.877–1.590) 0.273
2.277 (1.283–4.041) 0.0049
for the multivariable analysis were available in 9,364 patients.Outco
ization
izationthe transradial group, suggesting that this patient popula-
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34tion may benefit relatively more from a dedicated bleeding
minimization strategy (29). An alternative hypothesis that
merits further investigation is that only centers with high
radial PCI volumes were confident in randomizing STEMI
patients in the study; therefore, STEMI patients in the
study may simply serve to identify operators particularly
experienced for transradial PCI.
In patients with STEMI undergoing angioplasty, prompt
restoration of coronary flow is critical to the survival
advantage noted over medical treatment (30). Thus, it is
frequently felt that the use of the transradial route to restore
coronary flow is excessively time consuming in this setting
where, in addition, coronary anatomy is unknown, and the
need for large-lumen guiding catheters is highly unpredict-
able (16). The relatively slow rate of adopting TRI over time
in our regional STEMI registry suggests that the transition
from the transfemoral to the transradial route is a long-term
process in this challenging patient population. Although 10
of the 12 regional sites launched a TRI program in 2004 and
2005, several hundreds of PCI cases treated over a 3-year
time frame were deemed necessary to make TRI the more
prevalent access site in the acute setting of STEMI treat-
ment. Similarly, the cross-over from the radial to the
femoral access site peaked at almost 8% in 2006 and
subsequently declined to a much more acceptable 3% rate,
despite a progressive TRI increase over time.
Our study, in keeping with recent evidence (29), suggests
that the risks of transitioning toward the transradial route
over the conventional transfemoral approach in STEMI
patients, provided the process is undertaken in a step-wise
approach as part of a global TRI program, may be largely
outweighed by a lower mortality rate. Although a causal
relationship between the observed improved short-term
safety profile and the lower 2-year fatality rate cannot be
proven by our study, this hypothesis is of major potential
relevance for the whole medical community, and it is
currently being tested in the MATRIX (Minimizing Ad-
verse haemorrhagic events by TRansradial access site and
systemic Implementation of angioX) study.
Finally, based on a substantial reduction in the length of
hospitalization (28) as well as in access-site bleeding and
vascular complications (15,27,28), the widespread adoption
of TRI may dramatically impact the economic burden of
ACS in Western countries (31).
Study limitations. Our findings should be interpreted in the
ontext of our study design and its limitations. First, our
ata are observational. We used propensity score matching
o make the patient groups comparable according to the
easured confounders, and we successfully eliminated the
bserved differences. However, residual confounding cannot
e excluded.
Second, there was a substantial use of glycoprotein
Ib/IIIa inhibitors in our study population. The use of
ivalirudin, as compared with glycoprotein IIb/IIIa inhibi-ors, has been shown to decrease bleeding events in patients
ith myocardial infarction, which translated into a long-
erm mortality benefit (11). Whether our observations are
imilarly valid also for patients receiving a less aggressive
harmacological treatment remains to be determined.
leeding events were not prospectively collected in our
egistry; therefore, red blood cell transfusion and access-site
urgical repair was used as a surrogate for major bleeding or
ascular events.
It remains to be determined whether the reduction of
yocardial infarction and stroke at 2-year follow-up favor-
ng the transradial approach is a spurious finding or may
eflect a true long-term advantage of a strategy that mini-
izes bleeding and vascular events.
Finally, the use of secondary prevention medications was
ot prospectively collected in our registry. Therefore, we
annot rule out the possibility that a less aggressive imple-
entation of secondary prevention pharmacological mea-
ures in patients who experienced major in-hospital bleed-
ng and vascular events may at least partially explain the
bserved association between TRI and improved cardiovas-
ular outcomes (32).
onclusions
In patients undergoing angioplasty for acute myocardial
infarction, transradial treatment is associated with decreased
2-year mortality rates and a reduction in the need for
vascular surgery and/or blood transfusion compared with
transfemoral intervention. Large, randomized trials are
ongoing and will be necessary to confirm this observation.
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